Company Overview of Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1986
Key Executives for Boehringer Ingelheim Corporation
Chief Executive Officer and President
Chairman of the Board of Managing Directors
Vice President of Sales and Marketing
Compensation as of Fiscal Year 2015.
Boehringer Ingelheim Corporation Key Developments
Mallinckrodt, Perrigo & Hikma Reportedly Eye Roxane
Jun 30 15
Mallinckrodt public limited company (NYSE:MNK), Perrigo Company Public Limited Company (NYSE:PRGO) and Hikma Pharmaceuticals plc (LSE:HIK) are among the bidders for Roxane Laboratories, Inc., Bloomberg reported on June 29, 2015 citing sources in the know. The deal may value Roxane at €2 billion and Boehringer Ingelheim Corporation could select the buyer in a few weeks.
Boehringer Ingelheim Corporation Announces Phase II Data from its Investigational Compound Bi 655066
Mar 20 15
Boehringer Ingelheim Corporation announced Phase II data from its investigational compound BI 655066. Nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear or almost clear skin (described as PASI 90) after 12 weeks of treatment with BI 655066 compared to ustekinumab (77.1% versus 40% of patients). The study (NCT02054481) investigated the efficacy and safety of the new compound versus the commonly used psoriasis treatment, ustekinumab. BI 655066 had similar safety and tolerability to ustekinumab. The new data were presented in a late-breaker session at the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, California. In this primary Phase II analysis, the selective IL-23 inhibitor BI 655066 was superior to ustekinumab, an IL-12/23 inhibitor (PASI 90 77.1% vs. 40%). Using sPGA (static Physician Global Assessment) as a secondary outcome measure to determine psoriasis severity, 90% of patients in the study given BI 655066 had clear or almost clear skin compared with 67.5% for ustekinumab. These efficacy analyses were based on pooled dose results for BI 655066 of 90 and 180mg. In addition, results showed that more than double the percentage of psoriasis patients on BI 655066 achieved completely clear skin (PASI 100) after 12 weeks (46% of patients on BI 655066 compared to 17.5% patients on ustekinumab). The most commonly reported side-effects in the trial were a runny nose and sore throat (nasopharyngitis) and headache. In the study, 166 patients were randomly assigned to one of three dose groups of BI 655066 (18, 90 or 180 mg) or ustekinumab (one of two doses according to its label). All study treatments were given as an injection under the skin.
Boehringer and Eli Lilly Revise Operational Structure of Diabetes Alliance
Nov 3 14
Boehringer Ingelheim and Eli Lilly and Company have announced that they are revising the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90% of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance. The changes will be implemented starting January 1, 2015. The scope of the alliance will remain unchanged in the following 17 countries: US, Germany, Italy, Spain, France, UK, Republic of Ireland, Portugal, Canada, Japan, China, Australia, New Zealand, South Korea, Taiwan, Brazil, and Mexico. Under a revised agreement, Boehringer Ingelheim and Lilly will exclusively commercialize the respective molecules they brought to the alliance in all other countries under revised financial terms that will include an upfront payment and ongoing payments paid to Lilly in lieu of commission payments in those markets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|